High throughput crystallography of TB drug targets

A. C. Murillo, H. Y. Li, T. Alber, E. N. Baker, J. M. Berger, L. T. Cherney, M. M. Cherney, Yoon Song Cho, D. Eisenberg, C. R. Garen, C. W. Goulding, L. W. Hung, T. R. Ioerger, W. R. Jacobs, M. N.G. James, C. Kim, I. Krieger, J. S. Lott, R. Sankaranarayanan, B. W. SegelkeT. C. Terwilliger, F. Wang, S. Wang, J. C. Sacchettini

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Tuberculosis (TB) infects one-third of the world population. Despite 50 years of available drug treatments, TB continues to increase at a significant rate. The failure to control TB stems in part from the expense of delivering treatment to infected individuals and from complex treatment regimens. Incomplete treatment has fueled the emergence of multi-drug resistant (MDR) strains of Mycobacterium tuberculosis (Mtb). Reducing non-compliance by reducing the duration of chemotherapy will have a great impact on TB control. The development of new drugs that either kill persisting organisms, inhibit bacilli from entering the persistent phase, or convert the persistent bacilli into actively growing cells susceptible to our current drugs will have a positive effect. We are taking a 'multidisciplinary approach that will identify and characterize new drug targets that are essential for persistent Mtb. Targets are exposed to a battery of analyses including microarray experiments, bioinformatics, and genetic techniques to prioritize potential drug targets from Mtb for structural analysis. Our core structural genomics pipeline works with the individual laboratories to produce diffraction quality crystals of targeted proteins, and structural analysis will be completed by the individual laboratories. We also have capabilities for functional analysis and the virtual ligand screening to identify novel inhibitors for target validation. Our overarching goals are to increase the knowledge of Mtb pathogenesis using the TB research community to drive structural genomics, particularly related to persistence, develop a central repository for TB research reagents, and discover chemical inhibitors of drug targets for future development of lead compound.

Original languageEnglish (US)
Pages (from-to)127-139
Number of pages13
JournalInfectious Disorders - Drug Targets
Issue number2
StatePublished - Jun 2007

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Microbiology (medical)


Dive into the research topics of 'High throughput crystallography of TB drug targets'. Together they form a unique fingerprint.

Cite this